Welcome to our dedicated page for Altimmune news (Ticker: ALT), a resource for investors and traders seeking the latest updates and insights on Altimmune stock.
Altimmune Inc (ALT) is a clinical-stage biopharmaceutical company pioneering peptide-based therapeutics for obesity, metabolic disorders, and liver diseases. This page serves as the definitive source for verified news and press releases directly from the company and trusted financial publications.
Investors and researchers will find timely updates on clinical trial progress, including developments for pemvidutide, the company’s GLP-1/glucagon dual receptor agonist candidate. Track regulatory milestones, partnership announcements, and strategic initiatives that shape Altimmune’s research pipeline.
Our curated news feed includes earnings reports, scientific presentations, and manufacturing updates, providing a holistic view of the company’s trajectory. All content is rigorously vetted to ensure alignment with financial reporting standards and clinical accuracy.
Bookmark this page for efficient access to Altimmune’s latest material events. Check regularly for updates on pivotal studies in metabolic-associated steatohepatitis (MASH) and obesity therapeutics, ensuring you stay informed on developments impacting this innovative biopharma leader.
Altimmune (NASDAQ: ALT) has initiated the RECLAIM Phase 2 trial for pemvidutide in Alcohol Use Disorder (AUD). The trial will evaluate the drug's efficacy and safety across approximately 15 U.S. sites, enrolling about 100 subjects in a 1:1 randomization to receive either 2.4 mg pemvidutide or placebo weekly for 24 weeks.
The trial's primary endpoint focuses on changes in alcohol consumption, measured by heavy drinking days per week at Week 24. Pemvidutide, a novel GLP-1/glucagon dual receptor agonist, is also being studied for MASH, obesity, and alcohol liver disease (ALD). The company expects topline data from the IMPACT Phase 2b trial in MASH in Q2 2025 and plans to initiate a Phase 2 trial in ALD in Q3 2025.
The study addresses a significant market opportunity, with over 28 million individuals in the U.S. affected by AUD, where less than 10% receive treatment and 2% or less use approved medications.
Altimmune (Nasdaq: ALT), a late clinical-stage biopharmaceutical company focused on liver and cardiometabolic diseases, has announced its participation in two upcoming investor conferences. Management will attend the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, with a fireside chat at 10:00 AM ET, and the Jefferies Global Healthcare Conference on June 4, 2025, with a fireside chat at 9:55 AM ET. Both events will take place in New York, and webcasts will be available on Altimmune's website. The company will also be available for one-on-one meetings during these conferences.
Altimmune (ALT) has secured a credit facility of up to $100 million from Hercules Capital (HTGC), with an initial $15 million tranche funded at closing. The company, which had $150 million in cash as of March 31, 2025, will use the funds to support the development of pemvidutide, its GLP-1/glucagon dual receptor agonist. The remaining tranches include $25 million available in 2025 and $60 million in 2026, subject to clinical and financial milestones.
Pemvidutide is currently in a Phase 2b IMPACT trial for MASH with top-line data expected in Q2 2025. The company also plans to initiate Phase 2 trials for Alcohol Use Disorder and Alcohol Liver Disease in Q2 and Q3 2025. The loan features interest-only payments for 24 months (extendable to 42 months) and matures in 48 months.
Altimmune (NASDAQ: ALT), a late clinical-stage biopharmaceutical company, has scheduled its first quarter 2025 financial results announcement for Tuesday, May 13, 2025. The company will host a conference call and webcast at 8:30 am E.T. on the same day, during which management will discuss the financial performance and provide a business update.
Investors can access the webcast through Altimmune's Investor Relations website, and participants wishing to join the call can register to receive dial-in information. A replay of the call will be available on the company's website for up to three months following the event.
Altimmune (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, has announced its upcoming participation in the Citizens Life Sciences Conference. The company's management team will engage in a fireside chat scheduled for Wednesday, May 7, 2025, at 9:30 a.m. EDT.
Interested parties can access the session through a webcast available in the Events section of the Altimmune website. This participation demonstrates the company's continued engagement with the investment community and commitment to transparency in communications.
Altimmune (Nasdaq: ALT) has announced a virtual R&D Day scheduled for March 13, 2025 at 12:00 pm Eastern Time. The event will showcase presentations from Key Opinion Leaders (KOLs) focusing on multiple therapeutic areas for pemvidutide:
- Obesity treatment applications
- MASH (Metabolic Dysfunction-Associated Steatohepatitis)
- Two additional newly FDA-cleared indications
The R&D Day will cover the scientific basis for pemvidutide across these indications, review existing clinical data, and outline development strategies. A significant highlight will be discussing the upcoming topline data from the IMPACT Phase 2b trial in MASH, expected in Q2 2025. The event will be accessible through https://investorday.altimmune.com and the company's website Events section.
Altimmune (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, has announced its upcoming participation in the Leerink Global Healthcare Conference in March 2025. The company's management team will engage in a fireside chat session during the conference.
The event will be accessible via webcast through the Events section of the Altimmune website, providing investors and interested parties an opportunity to follow the discussion remotely.
FAQ
What is the current stock price of Altimmune (ALT)?
What is the market cap of Altimmune (ALT)?
